Heptares Overview

  • Founded
  • 2007
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 75
Employees
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $5.5M
Latest Deal Amount
  • Investors
  • 1

Heptares General Information

Description

Developer of a novel drug designed to target G protein-coupled receptors. The company's drugs have the potential to transform the treatment of Alzheimer's disease, ADHD, diabetes, schizophrenia, migraine, and other diseases, enabling physicians to treat critical diseases.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Primary Office
  • Granta Park
  • Great Abington
  • Cambridge CB21 6GP
  • England, United Kingdom
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Heptares Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Grant 28-Sep-2015 $5.5M Completed Generating Revenue
4. Merger/Acquisition 23-Feb-2015 00000 000.00 00000 Completed Generating Revenue
3. Later Stage VC (Series B) 27-Jun-2013 0000 000.00 Completed Generating Revenue
2. Early Stage VC (Series A) 24-Feb-2009 $30.3M $30.3M 000.00 Completed Generating Revenue
1. Seed Round 13-Aug-2007 Completed Startup
To view Heptares’s complete valuation and funding history, request access »

Heptares Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view Heptares’s complete cap table history, request access »

Heptares Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a novel drug designed to target G protein-coupled receptors. The company's drugs have the potential to tran
Drug Discovery
Cambridge, United Kingdom
75 As of 2014
000.00
0000000000

0000000

unt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco lab
0000 000000000
Boston, MA
0 As of 0000
00000
000000000 00000

000000 0

abore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nis
0000 000000000
Burlingame, CA
00 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Heptares Competitors (126)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aileron Therapeutics Formerly VC-backed Boston, MA 0 00000 000000000 00000
000000 00000000000 Formerly VC-backed Burlingame, CA 00 00000 000000 - 000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
0000000 000000 Formerly VC-backed Lyon, France 000 00000 00000000 00000
00000000000 Formerly VC-backed Philadelphia, PA 00 000.00 000000&0 000.00
You’re viewing 5 of 126 competitors. Get the full list »

Heptares Patents

Heptares Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201820458-D0 Ox1 antagonists Ceased 14-Dec-2018 0000000000
GB-201819960-D0 Pharmaceutical compounds Ceased 07-Dec-2018 0000000000
EP-3891140-A1 Bicyclic aza compounds as muscarinic m1 and/or m4 receptor agonists Pending 07-Dec-2018 0000000000
GB-201819961-D0 Pharmaceutical compounds Ceased 07-Dec-2018 000000000
EP-3891143-A1 Quinolinone and benzoxazine derivatives as muscarinic m1 and/or m4 receptor agonists Pending 07-Dec-2018 A61P25/18
To view Heptares’s complete patent history, request access »

Heptares Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Heptares Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Blackstone Life Sciences PE/Buyout Minority 000 0000 000000 0
MVM Partners Growth/Expansion Minority 000 0000 000000 0
Novartis Venture Fund Corporate Venture Capital 000 0000 000000 0
Omega Funds PE/Buyout Minority 000 0000 000000 0
Stanley Family Foundation Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Heptares Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 0000 30-Nov-2016 0000000000 0000 Biotechnology 00000 000
To view Heptares’s complete acquisitions history, request access »

Heptares Subsidiaries (1)

Company Name Industry Location Founded
00000000 000000 Biotechnology Zurich, Switzerland
To view Heptares’s complete subsidiaries history, request access »